Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1A/1B Dose Escalation and Expansion Study of SBP-101 in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Trial Profile

Phase 1A/1B Dose Escalation and Expansion Study of SBP-101 in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Nov 2018

At a glance

  • Drugs SBP 101 (Primary) ; Gemcitabine; Paclitaxel
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Adverse reactions
  • Sponsors Sun BioPharma
  • Most Recent Events

    • 05 Nov 2018 According to a Sun BioPharma media release, the third clinical site at the Austin Health Cancer Trials Centre in Melbourne has been opened for enrollment.
    • 13 Aug 2018 According to a Sun BioPharma media release, The Austin Health Cancer Trials Centre in Melbourne, The Adelaide Cancer Centre in Adelaide, The Blacktown Cancer and Haematology Centre in Sydney are the three sites for this trial. Early results from first portion of the trial expected by early fourth quarter of 2018.
    • 27 Jul 2018 According to a Sun BioPharma media release, first patients began treatment on June 13, 2018 in Australia and the United States.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top